It means touch, pressure or contact feels less clear, less strong or different from your own previous baseline. The location, timing, associated symptoms and impact are more useful than comparing yourself with a universal standard.

No. Sensation describes what touch or pressure feels like, while libido means sexual desire. Desire, arousal, lubrication, pain and orgasm can overlap with sensation but should be assessed separately.

No. Reduced sensation may contribute for some women, but orgasm is influenced by clitoral stimulation, arousal, medicines, health, pelvic-floor function, psychological context and other factors.

Pregnancy, vaginal birth, tears, assisted delivery, scar tissue, pelvic-floor injury and nerve stretch may alter awareness or comfort. Postpartum recovery varies and deserves individual assessment.

Menopause-related GSM may cause dryness, irritation, fragility or pain that affects sexual comfort and responsiveness. Reduced sensation alone does not confirm GSM, and other contributors should be considered.

Yes. Some medicines and conditions affecting hormones, nerves, circulation, mood or energy may alter sexual experience. Do not stop prescribed treatment without advice from the responsible prescriber.

They can influence arousal, attention and sexual experience, but that does not mean a physical change is imagined. A good assessment considers physical, emotional and relationship factors without making assumptions.

Seek urgent medical assessment for sudden or rapidly worsening genital numbness with leg weakness or numbness, severe back pain, difficulty passing urine, loss of bladder or bowel control, or numbness around the inner thighs or buttocks.

Assessment should clarify where and when sensation changed, related pain, dryness, bleeding, urinary or neurological symptoms, childbirth, surgery, menopause, health conditions, medicines, pelvic-floor factors and emotional context.

An examination may be recommended to assess tissue, scars, skin change, infection, pain, prolapse or pelvic-floor findings. It is explained first, requires your consent and can be paused or declined.

Nu-V is WHC’s fractional CO₂ vaginal laser procedure. It delivers controlled energy in microscopic treatment zones with the intention of prompting a local healing and tissue-remodelling response.

It may be discussed when assessment suggests a tissue-related contributor. The proposed action is local tissue remodelling, but evidence specifically showing restored sensation is limited and individual response is uncertain.

No nerve repair or restored nerve function can be promised. Sudden numbness, nerve-type pain, weakness or bladder and bowel change requires appropriate medical assessment rather than a laser-first approach.

No. Libido is sexual desire and is not a guaranteed laser outcome. Hormonal, medical, psychological, relationship and medication factors may need their own assessment and treatment.

Nu-V cannot be promised to improve orgasm. Orgasm concerns may require broader sexual-function, medicine, hormonal, pelvic-floor or psychosexual assessment.

A lubrication benefit cannot be guaranteed. Where dryness or GSM is the main concern, the cause and established treatment options should be assessed directly.

It may be discussed with a woman who has a persistent, bothersome change, a possible tissue-related contributor, satisfactory safety checks, realistic expectations and a clear understanding of the limited evidence.

Treatment is postponed during pregnancy and when there is active infection, unexplained bleeding, an undiagnosed lesion or another condition requiring treatment or investigation first.

Timing depends on postpartum healing, breastfeeding, symptoms and future pregnancy plans. Recent childbirth is not a reason to rush into treatment because tissues and pelvic-floor function may continue to change.

Anticoagulants and antiplatelets require an individual review. Never stop aspirin, warfarin, apixaban or another prescribed medicine unless the responsible prescriber specifically instructs you.

Previous pelvic surgery, mesh, reconstruction, radiotherapy or significant scarring may affect safety and suitability. Additional records or specialist input may be needed before any decision.

You are positioned similarly to a cervical-screening examination. A sterile vaginal probe delivers controlled fractional CO₂ energy to the selected area. The laser application is usually brief within a longer appointment.

Anaesthetic is not routinely required. Sensation varies and may include pressure, warmth, vibration, tingling or discomfort. Tell the practitioner if you need a pause or want treatment stopped.

Temporary warmth, tenderness, swelling, irritation, light spotting or watery discharge may occur. Important risks include infection, bleeding, burns, ulceration, scarring, persistent pain, painful intercourse or altered sensation.

Many women return to ordinary non-strenuous activity quickly. Written aftercare may advise avoiding vaginal intercourse, tampons, swimming and strenuous exercise for about five days or as individually directed.

There is no universal number. One session or a reviewed course of three may be discussed, but further treatment should depend on healing, tolerability and whether a meaningful benefit is occurring.

There is no guaranteed timetable. Any change should be assessed against the symptom and baseline agreed before treatment, allowing for healing and recognising that no meaningful improvement may occur.

Duration is uncertain and varies. An annual top-up is a priced option after reassessment, not a promise that a benefit will last for one or two years.

The clinician should review the original concern, healing, diagnosis and other contributors. The next step may be no further procedure, pelvic-health care, medicine or hormonal review, psychosexual support or specialist referral.

Current prices are £599 nurse-led or £799 doctor-led for one session; £1,200 nurse-led or £1,800 doctor-led for a course of three; and £400 nurse-led or £600 doctor-led for an annual top-up after reassessment. Consultation fees are shown above.

Nu-V is offered through WHC clinics, but practitioner, appointment type and treatment availability can vary. The care team should confirm the appropriate clinic and clinician before you travel.

Nu-V uses a fractional CO₂ vaginal laser with a sterile treatment probe. The clinician should explain the device, treatment area, settings, infection-control arrangements and why it is being considered for you.

It is an elective private procedure that may be discussed for symptom-related tissue concerns after clinical assessment. It should not be presented as a medical cure or as an appearance-only treatment that guarantees sexual outcomes.

No. Nu-V and labiaplasty are different procedures with different aims. Nu-V does not remove or reshape labial tissue, and neither procedure should be used as a substitute for assessing the concern you actually have.

External appearance is not the main outcome of this reduced-sensation pathway, and no visible change can be promised. A photograph cannot demonstrate sensation, pleasure, nerve recovery or sexual function.

The term “clitoral atrophy” may be used for changes in appearance, size, exposure or sensation and needs careful assessment. An intravaginal Nu-V procedure should not be assumed to treat clitoral tissue or restore clitoral sensation.

Women experience penetration very differently, and many need vulval or clitoral stimulation for pleasure or orgasm. There is no single normal level of vaginal sensation, but a new, marked or distressing change deserves assessment.